Our Newsletter “Deal Capsule Life Sciences” offers regular insights into selected transactions, developments in the M&A market and the issues shaping the transaction landscape of the global life sciences sector – from risk-conscious acquisition strategies to innovation priorities in areas such as oncology and immunology. In addition, our experts provide further insights into market trends and shed light on a specific topic relating to the global transactions and investment market.
Register now:
Archive Issues
Here you will find the past issues of the newsletter, covering selected deals, developments in the M&A market, and the key issues shaping the sector’s transaction market.
- Current Issue
- Archive
An overview of the topics in the current issue (August 2026)
- Deal value and volume: H1 2026 saw transaction activity accelerate, with larger deal sizes reflecting demand for growth assets and the need to address impending exclusivity losses. Available capital and continued appetite for innovation-supported dealmaking activity across the sector.
- Strategic priority: Private equity investors remained active, particularly in corporate carve-out situations, consolidation opportunities and portfolio repositioning initiatives aimed at creating value.
- M&A focus: Deal activity gravitated toward late-stage and near-commercial assets offering revenue visibility and commercial scalability. Acquirers also targeted platform technologies and AI-enabled capabilities to strengthen R&D processes, accelerate product development, and support commercial execution.
- Ruling therapy areas: Cardio-metabolic diseases, immunology, oncology, and neurology attracted substantial investor interest, with activity centered on clinically validated assets and pipeline expansion opportunities.
Your contact
Christian Klingbeil
Partner, Deal Advisory, Valuation, Head of Life Sciences & Chemicals
KPMG AG Wirtschaftsprüfungsgesellschaft